These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 23182972

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus.
    Farombi-Oghuvbu I, Matthews T, Mayne PD, Guerin H, Corcoran JD.
    Arch Dis Child Fetal Neonatal Ed; 2008 Jul; 93(4):F257-60. PubMed ID: 18218660
    [Abstract] [Full Text] [Related]

  • 5. Factors affecting N-terminal pro-B-type natriuretic peptide levels in preterm infants and use in determination of haemodynamic significance of patent ductus arteriosus.
    Harris SL, More K, Dixon B, Troughton R, Pemberton C, Horwood J, Ellis N, Austin N.
    Eur J Pediatr; 2018 Apr; 177(4):521-532. PubMed ID: 29352349
    [Abstract] [Full Text] [Related]

  • 6. Brain natriuretic peptide and N-terminal brain natriuretic peptide for the diagnosis of haemodynamically significant patent ductus arteriosus in preterm neonates.
    Gokulakrishnan G, Kulkarni M, He S, Leeflang MM, Cabrera AG, Fernandes CJ, Pammi M.
    Cochrane Database Syst Rev; 2022 Dec 08; 12(12):CD013129. PubMed ID: 36478359
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Diagnosing significant PDA using natriuretic peptides in preterm neonates: a systematic review.
    Kulkarni M, Gokulakrishnan G, Price J, Fernandes CJ, Leeflang M, Pammi M.
    Pediatrics; 2015 Feb 08; 135(2):e510-25. PubMed ID: 25601976
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. B-type and N-terminal pro-B-type natriuretic peptides are equally useful in assessing patent ductus arteriosus in very preterm infants.
    König K, Guy KJ, Drew SM, Barfield CP.
    Acta Paediatr; 2015 Apr 08; 104(4):e139-42. PubMed ID: 25488470
    [Abstract] [Full Text] [Related]

  • 12. [Value of amino-terminal pro-brain natriuretic peptide as a predictive marker of symptomatic patent ductus arteriosus in preterm infants].
    Lu KS, Guo XL, Lv JF, Huang SL, Yang CH, Zou ZH, Chen ZJ, Lai CH, Yang BY.
    Zhongguo Dang Dai Er Ke Za Zhi; 2015 Nov 08; 17(11):1160-4. PubMed ID: 26575871
    [Abstract] [Full Text] [Related]

  • 13. Early NT-proBNP levels as a screening tool for the detection of hemodynamically significant patent ductus arteriosus during the first week of life in very low birth weight infants.
    Rodriguez-Blanco S, Oulego-Erroz I, Gautreaux-Minaya S, Perez-Muñuzuri A, Couce-Pico ML.
    J Perinatol; 2018 Jul 08; 38(7):881-888. PubMed ID: 29785059
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Urinary NT-proBNP, NGAL, and H-FABP may predict hemodynamic relevance of patent ductus arteriosus in very low birth weight infants.
    Tosse V, Pillekamp F, Verde P, Hadzik B, Sabir H, Mayatepek E, Hoehn T.
    Neonatology; 2012 Jul 08; 101(4):260-6. PubMed ID: 22222353
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Point-of-care testing for B-type natriuretic peptide in premature neonates with patent ductus arteriosus.
    Kalra VK, DeBari VA, Zauk A, Kataria P, Myridakis D, Kiblawi F.
    Ann Clin Lab Sci; 2011 Jul 08; 41(2):131-7. PubMed ID: 21844570
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.